However, KBI treatment had no effects on serum insulin levels, the OGTT and ITT results, liver weight, dyslipidemia, liver steatosis and injury, ALT and AST levels (Figure 2D,F–I; Figure S5A–G, Supporting Information). The gene discussed is INS; the disease is fatty liver disease.